Explore our ongoing and completed clinical trials below.
| Clinical trial | Phase | MOA | Disease state | Investigational therapy | Associated publications |
|---|---|---|---|---|---|
|
Topical roflumilast cream (ARQ-151) phase 3 plaque psoriasis open-label extension (DERMIS-OLE) Ongoing |
Phase: 3 | MOA: PDE4 inhibitor | Disease state: Plaque psoriasis | Investigational therapy: Roflumilast cream (ARQ-151) | |
|
Topical roflumilast cream (ARQ-151) phase 3 atopic dermatitis study (INTEGUMENT-2) Completed |
Phase: 3 | MOA: PDE4 inhibitor | Disease state: Atopic dermatitis | Investigational therapy: Roflumilast cream (ARQ-151) | |
|
Topical roflumilast cream (ARQ-151) phase 3 atopic dermatitis study (INTEGUMENT-1) Completed |
Phase: 3 | MOA: PDE4 inhibitor | Disease state: Atopic dermatitis | Investigational therapy: Roflumilast cream (ARQ-151) | |
|
Topical roflumilast cream (ARQ-151) phase 2b plaque psoriasis study Completed |
Phase: 2b | MOA: PDE4 inhibitor | Disease state: Plaque psoriasis | Investigational therapy: Roflumilast cream (ARQ-151) | Associated publications: Trial of roflumilast cream for chronic plaque psoriasis |
|
Topical roflumilast cream (ARQ-151) phase 2 plaque psoriasis open-label long-term safety study Completed |
Phase: 2 | MOA: PDE4 inhibitor | Disease state: Plaque psoriasis | Investigational therapy: Roflumilast cream (ARQ-151) | |
|
Topical roflumilast cream (ARQ-151) phase 2 atopic dermatitis proof of concept study Completed |
Phase: 2 | MOA: PDE4 inhibitor | Disease state: Atopic dermatitis | Investigational therapy: Roflumilast cream (ARQ-151) | |
|
Topical roflumilast cream (ARQ-151) phase 1/2a plaque psoriasis study Completed |
Phase: 1/2a | MOA: PDE4 inhibitor | Disease state: Plaque psoriasis | Investigational therapy: Roflumilast cream (ARQ-151) | Associated publications: Roflumilast cream for plaque psoriasis: results from a phase 1/2a randomized, controlled study |
|
Topical roflumilast cream (ARQ-151) open-label extension trial in atopic dermatitis (INTEGUMENT-OLE) Ongoing |
Phase: 3 | MOA: PDE4 inhibitor | Disease state: Atopic dermatitis | Investigational therapy: Roflumilast cream (ARQ-151) |